Background: Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models. We evaluated the safety, tolerability, and pharmacokinetic properties of GDC-0575 alone and in combination with gemcitabine. Antitumor activity and Chk1 pathway modulation were assessed.
Introduction
Several pre-clinical studies have shown that inhibition of the serine/threonine kinase checkpoint kinase 1 (Chk1) potentiates the efficacy of DNA-damaging chemotherapy by converting an otherwise transient genotoxic insult into a cytotoxic effect, particularly in tumor cells that lack functional p53 [1, 2] .
GDC-0575 is an orally bioavailable, potent, and selective small-molecule inhibitor of Chk1 [3] , the antitumor activity of which is broader and more profound when combined with gemcitabine.
This first-in-human study was designed to characterize the safety, pharmacokinetic (PK), pharmacodynamics (PD) properties and preliminary activity of GDC-0575 alone and in combination with gemcitabine in patients with refractory solid tumors.
Methods

Study design
This was a phase I open-label study with two treatment arms (supplementary Figure S1 , available at Annals of Oncology online). In the dose escalation stage (stage I), patients were enrolled in a 3 þ 3 (arm 1) or 3 þ 3 þ 3 (arm 2) design to determine the maximum tolerated dose (MTD). A 3 þ 3 þ 3 design was used for the GDC-0575 and gemcitabine arm to limit the chance of falsely halting dose escalation due to gemcitabine toxicities [4] . Patients in arm 1 (monotherapy) received oral GDC-0575 15-90 mg (supplied by Genentech Inc., South San Francisco, CA) alone daily for three consecutive days starting on days 1, 8, and 15 of a 21-day cycle. Patients in arm 2 (GDC-0575 and gemcitabine combination) received i.v. gemcitabine 1000 mg/m 2 on days 1 and 8 of a 21-day cycle, followed by a single oral dose of GDC-0575 15-60 mg on days 2 and 9, approximately 24 hours after gemcitabine administration based upon preclinical studies [5] (arm 2a; except for the first cohort that received i.v. gemcitabine 750 mg/m 2 to confirm safety of initial 15 mg GDC-0575 dose in the combination arm). Alternatively, patients received i.v. gemcitabine 500 mg/m 2 in 21-day cycles (as above) or in 28-day cycles biweekly, followed by a single oral dose of GDC-0575 45-105 mg approximately 24 hours after each gemcitabine dose (arm 2 b). Stage II enrolled disease-specific cohorts at the recommended phase II dose of 45 mg GDC-0575 þ gemcitabine 1000 mg/m 2 (arm 2a) or 80 mg GDC-0575 þ gemcitabine 500 mg/m 2 (arm 2 b) and allowed a flexible 21-or 28-day cycle based upon overall tolerability and most often driven by hematologic parameters. The MTD was defined as the highest dose at which one-third or less of patients experienced a dose-limiting toxicity (DLT). A DLT was defined as study drug-related adverse events (AE) occurring within the first 21 (arms 1 and 2a) or 28 (arm 2b) days, including (GDC-0575 monotherapy arm) grade >3 lasting >7 days or grade 4 neutropenia or thrombocytopenia, grade !3 elevation of alanine aminotransferase (ALT) or aspartate transaminase (AST); and (combination arms) grade 3 thrombocytopenia associated with clinically significant bleeding or grade !4, grade !4 neutropenia or grade !3 elevation of ALT or AST lasting >7 days, grade !3 febrile neutropenia. Symptomatic hypotension or decrease in left ventricular ejection fraction to <50% were also considered DLT.
Patients
Patients age !18 years had histologically or cytologically documented, locally advanced, or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable, Eastern Cooperative Oncology Group performance status of 0-1, and evaluable disease or measurable disease per RECIST v1.1. [6] . Patients were required to have adequate bone marrow and organ function including neutrophil count !1500/ll, platelet count !100, 000/ll, hemoglobin !10 g/dl, total bilirubin 1.5Â the upper limit of normal, and AST and ALT 3Â the upper limit of normal. Excluded patients had severe uncontrolled systemic disease or serious cardiac dysfunction, including left ventricular ejection fraction <55%, or contraindication to anti-Chk1 or gemcitabine therapy. For expansion cohorts, prior gemcitabine was not allowed.
The protocol was approved by Institutional Review Boards and was conducted in accordance with International Conference on Harmonization E6 Guidelines for Good Clinical Practice. Written informed consent was obtained for all patients prior to performing study-related procedures in accordance with federal and institutional guidelines. The study was registered on ClinicalTrials.gov (NCT01564251).
Safety assessments
All patients who received !1 dose of study treatment were assessed for safety. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0.
PK assessments
PK assessments of GDC-0575 and gemcitabine were performed in all patients as described in Supplementary Methods, available at Annals of Oncology online.
Activity outcomes
Disease status was assessed using RECIST v1.1 at screening, at the end of cycles 2 and 4, during the last week of every third cycle beyond cycle 4 and at the end of study treatment. Patients with no post-baseline tumor response assessment were considered non-responders. Time on study was defined as time from first treatment dose (GDC-0575 or gemcitabine) to study discontinuation.
Biomarker assessments
Archival tumor tissue was used for assessment of mutational status of TP53. Pharmacodynamic changes in the Chk1 pathway marker pCDK1/2 and Ki-67 were evaluated in formalin-fixed and paraffin-embedded serial tumor biopsies as described in Supplementary Methods, available at Annals of Oncology online.
Statistical methods
This study was intended to obtain descriptive preliminary safety, PK, and activity information in the treated populations, and as such, sample sizes do not reflect explicit power and type I error considerations (see Supplementary Methods, available at Annals of Oncology online).
Results
Patient characteristics
A total of 102 patients were enrolled and received !1 dose of GDC-0575. Twenty-one patients received GDC-0575 monotherapy (arm 1) and 81 patients received GDC-0575 in combination with gemcitabine (n ¼ 52 in arm 2a and n ¼ 29 in arm 2b). The demographics and disease characteristics are shown in Table 1 . Ninety-two (90%) patients were gemcitabine-naive. observed in 12 patients overall in stage I. Of 21 patients who received single-agent GDC-0575, 3 experienced DLTs (1 out of 6 patients at 60 mg and 2 out of 5 at 90 mg) of grade 4 neutropenia; therefore, GDC-0575 60 mg was declared the MTD for monotherapy. Nine patients were treated at GDC-0575 60 mg monotherapy.
Five patients who received GDC-0575 20-60 mg in combination with gemcitabine 1000 mg/m 2 in stage I experienced DLTs: grade 3 ALT increase and grade 3 AST increase (n ¼ 1), grade 4 thrombocytopenia (n ¼ 1), grade 4 thrombocytopenia (n ¼ 1), grade 4 febrile neutropenia and grade 4 thrombocytopenia (n ¼ 1), and grade 3 febrile neutropenia and grade 4 thrombocytopenia (two events) (n ¼ 1). GDC-0575 60 mg in combination with gemcitabine 1000 mg/m 2 was found to exceed MTD, and GDC-0575 45 mg in combination with gemcitabine 1000 mg/m 2 was declared the MTD with 1 of 6 DLT-evaluable patients experiencing DLT. Overall, 29 patients were treated with GDC-0575 45 mg in combination with gemcitabine 1000 mg/m 2 (stages I and II). Four patients who received GDC-0575 60-105 mg in combination with gemcitabine 500 mg/m 2 in stage I experienced DLTs: one patient each with grade 4 thrombocytopenia, grade 4 neutropenia, grade 4 thrombocytopenia, or grade 3 febrile neutropenia. GDC-0575 105 mg in combination with gemcitabine 500 mg/m 2 was found to exceed MTD, and GDC-0575 80 mg in combination with gemcitabine 500 mg/m 2 was declared the MTD with one of six DLT-evaluable patients experiencing DLT. Overall, 16 patients were treated at GDC-0575 80 mg in combination with gemcitabine 500 mg/m 2 (stages I and II).
Overall safety
AEs in the overall safety evaluable population (N ¼ 102) are described in supplementary Table S1 , available at Annals of Oncology online. The most common AEs (!15%) reported as related to GDC-0575 and/or gemcitabine were hematological and included neutropenia, leukopenia, thrombocytopenia and anemia. The frequency of hematologic and non-hematologic AEs was similar among the patients treated at the MTD (GDC-0575 45 mg in combination with gemcitabine 1000 mg/m 2 : n ¼ 29; GDC-0575 80 mg in combination with gemcitabine 500 mg/m 2 : n ¼ 16). Overall, 50 patients (49%) experienced at least one serious AEs (SAEs) regardless of attribution. Twenty-seven of these patients experienced SAEs assessed by the investigators as related to study treatment (supplementary Table S2 , available at Annals of Oncology online). Five deaths occurred during this study. One event of sepsis on study day 55 was reported by the investigator as related to the combination of GDC-0575 þ gemcitabine. This patient had underlying pneumonia with Pseudomonas aeruginosa detected in sputum, thrombocytopenia, anemia, and neutropenia. The patient elected DNR status and declined aggressive supportive measures. Of the four deaths unrelated to GDC-0575 and gemcitabine, one event of sepsis occurred during safety follow-up on day 29 in a patient who had discontinued study drug on day 8 for DLT of grade 4 thrombocytopenia, one unexplained death occurred on day 260 in a patient with small-cell lung cancer with underlying shortness of breath and wheezing who was found unresponsive at home and no autopsy done. Two deaths occurred due to progressive disease.
Discontinuation reasons and dose modifications
Of 16 patients (16%) discontinued from GDC-0575 and/or gemcitabine treatment due to AEs, 15 patients experienced related AEs. In arm 1: grade 3 ALT increase, grade 3 AST increase, and grade 2 alkaline phosphatase increase (n ¼ 1); grade 4 neutropenia (n ¼ 1); grade 2 hypersensitivity (n ¼ 1). In arm 2a: grade 2 pneumonitis (n ¼ 1); grade 4 thrombocytopenia (n ¼ 2); grades 2 and 3 rash (n ¼ 1 each); grade 3 ALT increase, grade 4 AST increase, and grade 4 thrombocytopenia (n ¼ 1); grade 2 decreased ejection fraction (n ¼ 1); grade 4 atrial fibrillation and grade 2 hypotension (n ¼ 1). In arm 2b: grade 2 infection (n ¼ 1); grade 4 thrombocytopenia (n ¼ 1); grade 1 pyrexia and grade 2 rash (n ¼ 1); grade 3 fatigue, grade 3 hypotension, grade 2 pyrexia, and grade 3 neutropenia (n ¼ 1).
Patients in arm 1 received a median of 18 doses (range 1-150) of GDC-0575. In arms 2a and 2b, patients received a median of six doses (range 1-32) and four doses (range 1-43) of GDC-0575, respectively. Colony-stimulating factors such as granulocyte colony-stimulating factors were not administered prophylactically but were allowed per standard practice during the course of study treatment. Overall, 20 (20%) patients were treated with colony-stimulating factors (filgrastim, pegfilgrastim, and lenograstim). In arms 2a and 2b, 14 (27%) and 6 (21%) of patients received these agents as supportive care, respectively. No patients in arm 1 received colony-stimulating factors.
Among the 29 patients treated with GDC-0575 45 mg in combination with gemcitabine 1000 mg/m 2 , 18 patients (62%) had AEs that led to a dose reduction of gemcitabine and 2 patients (7%) had AEs that led to a dose reduction of GDC-0575. Among the 16 patients treated at GDC-0575 80 mg in combination with gemcitabine 500 mg/m 2 , 2 patients (13%) had AEs that led to a dose reduction of gemcitabine and 1 patient (6%) had an AE that led to a dose reduction of GDC-0575.
PK analysis
PK plasma samples from 96 patients were analyzed for GDC-0575 (supplementary Figure S2 , available at Annals of Oncology online), including 75 patients in the combination arm. Following oral administration, absorption of GDC-0575 was rapid and C max was mostly observed within 2 hours of dosing. GDC-0575 exposure [C max and area under the curve (AUC)] increased in an approximately dose-proportional manner with GDC-0575 doses ranging from 15 to 105 mg. Mean terminal t 1/2 on day 3 in the GDC-0575 monotherapy arm was approximately 22.8 hours.
PK plasma samples for gemcitabine were analyzed from 81 patients. Gemcitabine concentrations (supplementary Figure S3 , available at Annals of Oncology online) typically peaked at the end of the 30-minute i.v. infusion and declined rapidly thereafter, with a half-life of approximately 0.32 hours (range 0.23-0.54 hours). Mean gemcitabine exposure following the 1000 mg/m 2 dose (C max 19214 ng/ml; AUC 0-3 19 928 hours*ng/ml) was higher than the 750 mg/m 2 (C max 9610 ng/ml; AUC inf 6870 hours*ng/ml) or 500 mg/m 2 (C max 6919 ng/ml; AUC 0-3 4929 hour*ng/ml) gemcitabine doses. Gemcitabine exposures were similar to historical controls [5, 7, 8] and there was no trend of GDC-0575 dose affecting gemcitabine exposure.
Efficacy analysis and TP53 mutational status
Investigator assessments of best overall response were available for 90 of 102 patients with !1 post-baseline assessment; 12 patients (13%) did not have post-baseline tumor response assessments ( Figure 1 ). The median time on study was 2.4 months (range 0.1-19.5). A best overall response of stable disease or partial response was observed in 59 (66%) patients. There were four confirmed partial responses (4% of patients): one at GDC-0575 60 mg with gemcitabine 500 mg/m 2 in a patient with TP53-mutated uterine leiomyosarcoma and three at GDC-0575 80 mg with gemcitabine 500 mg/m 2 in patients with TP53-mutated undifferentiated pleomorphic sarcoma or triple negative breast cancer (TNBC), and TP53 wild-type non-small-cell lung cancer. One unconfirmed partial response was noted at GDC-0575 45 mg with gemcitabine 1000 mg/m 2 in a patient with TP53-mutated TNBC. Of the 29 patients treated at the RP2D 45 mg GDC-0575 þ gemcitabine 1000 mg/m 2 and the 16 patients treated at the RP2D 80 mg GDC-0575 þ gemcitabine 500 mg/m 2 , a best overall response of stable disease or partial response was observed in 15 (52%) and 8 (50%) patients, respectively.
Overall, 15 (15%) patients had stable disease for over 4 months: 1 out of 21 (5%) in the GDC-0575 monotherapy arm, 9 out of 52 (17%) in with gemcitabine 1000 mg/m 2 , and 5 out of 29 (17%) in with gemcitabine 500 mg/m 2 ( Figure 1 ).
Checkpoint activation and Chk1 modulation
TP53 status was available for 72 patients in arm 2. Responses (confirmed and unconfirmed) and stable disease for >4 months were observed in 12 out of 51 (24%) and 4 out of 21 (19%) of the TP53-mutated patients and TP53 wild-type patients, respectively. Tumor samples were obtained from 12 patients who had received gemcitabine 1000 mg/m 2 and GDC-0575 30 mg (n ¼ 3) or 45 mg (n ¼ 9). Seven patients were able to undergo biopsies before study treatment and after gemcitabine administration and four of these patients were also able to undergo biopsies after treatment with the combination of GDC-0575 and gemcitabine. 
Discussion
This first-in-human trial demonstrates that GDC-0575 can be administered safely as a monotherapy and with gemcitabine in patients with advanced cancer. The lack of GDC-0575 single-agent activity may in part be due to the dose intensity exposure cap achieved with the dose schedule tested (supplementary Figure S5 , available at Annals of Oncology online).
The neutropenia observed with single-agent GDC-0575 foreshadowed the challenge of combining with chemotherapy. Tolerability was modest when GDC-0575 was administered with gemcitabine 1000 mg/m 2 in 21-day cycles. Antitumor activity was limited with one patient with TP53-mutated TNBC who received GDC-0575 45 mg and gemcitabine 1000 mg/m 2 able to achieve an unconfirmed partial response and nine (17%) patients who had stable disease for over 4 months.
Preclinical studies conducted to simulate clinical gemcitabine exposures [9] indicated that chemopotentiation by Chk1 inhibition reduces the exposure threshold of gemcitabine required for antitumor activity (supplementary Figures S6 and S7 , available at Annals of Oncology online). In our clinical study, we were able to give GDC-0575 80 mg safely with gemcitabine 500 mg/m 2 . Although tolerability remained modest, antitumor activity appeared improved with GDC-0575 in combination with gemcitabine 500 mg/m 2 . Four patients achieved confirmed partial responses with GDC-0575 60 or 80 mg, including patients with TP53-mutated tumors. In addition, five (17%) patients experienced stable disease for longer than five months.
Despite achieving clinical exposures of GDC-0575 that exceeded preclinical thresholds for checkpoint abrogation as a single-agent and antitumor activity in combination with gemcitabine, the compelling chemopotentiation observed in xenograft models has been challenging to replicate in patients. Although preclinical data showed that chemopotentiation by Chk1 inhibition is effective in xenograft models that exhibit different intrinsic gemcitabine sensitivities (supplementary Figure S8 , available at Annals of Oncology online), the best efficacy was noted in models with elevated replication stress, that is, models more sensitive to both gemcitabine and Chk1 inhibition (supplementary Figure S9 , available at Annals of Oncology online). The difference in proliferative index in xenograft models compared with solid tumors in patients may reflect an intrinsic liability for cell cycle targeting agents such as antimetabolites (i.e. gemcitabine) and Chk1 inhibitors. This may be relevant to future patient selection and choice of chemotherapy combination for this treatment approach.
Given the small sample size, we were unable to identify a correlation with TP53 mutation status and clinical outcome by RECIST responses to identify a patient population responsive to this treatment strategy. However, the pre-and on-treatment biopsy IHC results from patients treated with GDC-0575 þ gemcitabine 1000 mg/m 2 hinted at a combination PD effect as observed in the preclinical setting. The limited clinical activity observed with the combination of GDC-0575 and gemcitabine 1000 mg/m 2 may reflect inadequate Chk1 inhibition to achieve chemopotentiation due dose limiting hematologic toxicities with this combination. Unfortunately, the lack of tumor tissue from the reduced dose gemcitabine combination limits our ability to make strong conclusions about the extent of Chk1 inhibition achieved with GDC-0575 (and any synergistic effects with gemcitabine) to draw comparison with dose-ranging preclinical data.
Overall our results highlight the complexity of optimizing dose and schedule selection and of applying predictive biomarkers to identify patients most likely to derive benefit from Chk1 inhibitor single-agent or combination treatment. Chk1 inhibitors with single-agent activity, such as GDC-0575, may be able to leverage multiple mechanisms of action to achieve antitumor activity. Strategies such as that pursued in this trial that combine lower dose intensity chemotherapy with greater Chk1 inhibition may be more successful in creating a broader therapeutic index by impacting additional Chk1 functions and exploiting multiple cancer vulnerabilities, including exacerbation of replication stress.
